PARP inhibitors, olaparib and talazoparib, have been granted FDA approval for the treatment of BRCA-associated HER2-negative metastatic BC based on the results from the Phase III Olympiad and EMBRACA trials [45]. This evidence concerns the gene PARP1 and breast cancer.